The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.

Also called NCT07103655

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07103655
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07103655. Non-randomized; no masking; primary purpose treatment. Start 2026-03-01 (actual); primary completion 2026-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
Acronym
BRAVE-HCM
Condition
Hypertrophic Cardiomyopathy (HCM)
Intervention (Drug)
mavacamten
Intervention (Drug)
Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol
Intervention (Drug)
diltiazem
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07103655
Content hash
5aad7a1548bfb25a1c646bbc468a5484136ace6483f1a3452ffed5fa45b3ae97